sulofenur

Sulofenur is a synthetic diarylsulfonylurea classified as an antineoplastic agent, developed for its broad spectrum of activity against various solid tumors in preclinical models[1][4][7]. Its precise mechanism of antitumor action remains unresolved, though evidence suggests it inhibits ribonucleotide reductases, which are crucial enzymes for DNA synthesis[7]. Sulofenur underwent extensive clinical investigations (phase I and II) as an oral small molecule for advanced cancers, but development was ultimately discontinued due to dose-limiting toxicities including hemolytic anemia and methemoglobinemia, and lack of significant efficacy in trials[3][4][6][7].

Other names

sulofenursulofenurum1-(4-chlorophenyl)-3-(2,3-dihydro-1H-inden-5-ylsulfonyl)ureaN-(5-indanylsulfonyl)-N'-(4-chlorophenyl)ureaN-((4-chlorophenyl)carbamoyl)-2,3-dihydro-1H-indene-5-sulfonamide